A Phase 3 interventional study of VX-659/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 6 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 74th largest by enrollment, is one of 8 that started in 2018, is one of 45 in phase 3, and was the 57th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 8 started in 2018.
This study's enrollment of 18 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 105th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 80th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-659, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects with F/F or F/MF genotypes.
The study was discontinued after completion of Part A due to Sponsor's discretion.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
Drug: VX-659/TEZ/IVA · Drug: IVA
VX-659/TEZ/IVA FDC tablet.
Also known as: VX-659/VX-661/VX-770, VX-659/tezacaftor/ivacaftor
IVA mono tablet.
Also known as: VX-770, ivacaftor
Maximum Observed Concentration (Cmax) of VX-659, TEZ, and IVA
Time frame: Day 1 and Day 15
Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, and IVA
Time frame: Day 8 and Day 15
Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of VX-659, TEZ, and IVA
Time frame: Day 1 and Day 15
Maximum Observed Concentration (Cmax) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame: Day 1 and Day 15
Observed Pre-Dose Concentration (Ctrough) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame: Day 8 and Day 15
Area Under the Concentration Versus Time Curve From Time 0 to 6 Hours (AUC0-6h) of TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame: Day 1 and Day 15
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 6 weeks)
A total of 18 participants were enrolled in this study. Two participants were enrolled but were not dosed in triple combination (TC) treatment period. Therefore, results are reported for 16 participants.
| Milestone | VX-659/TEZ/IVA |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| microgram per milliliter (mcg/mL) | VX-659/TEZ/IVA |
|---|---|
| VX-659: Day 1 | 1.81 ± 0.858 |
| VX-659: Day 15 | 2.55 ± 1.21 |
| TEZ: Day 1 | 4.53 ± 1.65 |
| TEZ: Day 15 | 5.22 ± 1.69 |
| IVA: Day 1 | 0.536 ± 0.208 |
| IVA: Day 15 | 0.733 ± 0.256 |
| mcg/mL | VX-659/TEZ/IVA |
|---|---|
| VX-659: Day 8 | 0.358 ± 0.259 |
| VX-659: Day 15 | 0.367 ± 0.283 |
| TEZ: Day 8 | 0.897 ± 0.488 |
| TEZ: Day 15 | 0.740 ± 0.421 |
| IVA: Day 8 | 0.289 ± 0.195 |
| IVA: Day 15 | 0.283 ± 0.241 |
| hour*mcg/mL (h*mcg/mL) | VX-659/TEZ/IVA |
|---|---|
| VX-659: Day 1 | 5.41 ± 3.65 |
| VX-659: Day 15 | 8.55 ± 4.50 |
| TEZ: Day 1 | 15.5 ± 5.36 |
| TEZ: Day 15 | 19.3 ± 7.26 |
| IVA: Day 1 | 1.64 ± 0.795 |
| IVA: Day 15 | 2.95 ± 1.18 |
| mcg/mL | VX-659/TEZ/IVA |
|---|---|
| M1-TEZ: Day 1 | 1.63 ± 0.553 |
| M1-TEZ: Day 15 | 5.04 ± 1.27 |
| M1-IVA: Day 1 | 1.25 ± 0.449 |
| M1-IVA: Day 15 | 1.73 ± 0.741 |
| mcg/mL | VX-659/TEZ/IVA |
|---|---|
| M1-TEZ: Day 8 | 3.56 ± 1.33 |
| M1-TEZ: Day 15 | 3.35 ± 1.23 |
| M1-IVA: Day 8 | 0.816 ± 0.491 |
| M1-IVA: Day 15 | 0.858 ± 0.672 |
| h*mcg/mL | VX-659/TEZ/IVA |
|---|---|
| M1-TEZ: Day 1 | 5.52 ± 2.87 |
| M1-TEZ: Day 15 | 25.2 ± 7.70 |
| M1-IVA: Day 1 | 3.60 ± 1.87 |
| M1-IVA: Day 15 | 6.98 ± 2.94 |
| Participants | VX-659/TEZ/IVA |
|---|---|
| Participants with AEs | 13 |
| Participants with SAEs | 1 |
Collected over From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 6 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VX-659/TEZ/IVA | 0/16 (0%) | 1/16 (6.3%) | 13/16 (81.3%) |
| Event | VX-659/TEZ/IVA |
|---|---|
| RashSkin and subcutaneous tissue disorders | 1/16 |
| Event | VX-659/TEZ/IVA |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 7/16 |
| HeadacheNervous system disorders | 6/16 |
| FatigueGeneral disorders | 3/16 |
| VomitingGastrointestinal disorders | 2/16 |
| PyrexiaGeneral disorders | 2/16 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 2/16 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 2/16 |
| Abdominal discomfortGastrointestinal disorders | 1/16 |
| Post-tussive vomitingGastrointestinal disorders | 1/16 |
| ChillsGeneral disorders | 1/16 |
| Age, Continuous(years) | VX-659/TEZ/IVA |
|---|---|
| Mean | 9.2 ± 1.4 |
| Sex: Female, Male(Participants) | VX-659/TEZ/IVA |
|---|---|
| Female | 5 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | VX-659/TEZ/IVA |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 14 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | VX-659/TEZ/IVA |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Jan 2019, 5 months.
Results were first posted in Feb 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →